Last edition
News about "lenalidomide"
Roche's Lunsumio Combo Meets Phase 3 CELESTIMO Endpoint
Roche’s Phase 3 CELESTIMO study shows statistically significant, clinically meaningful improvement in PFS with Lunsumio plus lenalidomide in R/R follicular lymphoma.
Lenalidomide | 18/09/2026 | By News Bureau
AbbVie Wins EU Approval for TEPKINLY in Combination with Lenalidomide and Rituximab
The European Commission has approved AbbVie's TEPKINLY with lenalidomide and rituximab as the first bispecific, chemotherapy-free treatment for Relapsed or Refractory Follicular Lymphoma in the second-line setting.
Lenalidomide | 07/07/2026 | By News Bureau
AbbVie Reports Positive Phase 3 Results for Epcoritamab in Diffuse Large B-Cell Lymphoma
AbbVie reported positive phase 3 results for epcoritamab plus lenalidomide, showing improved Progression-Free Survival (PFS) in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).
Lenalidomide | 01/07/2026 | By News Bureau | 110
US FDA Approves Roche's Lunsumio VELO for Subcutaneous Use in Follicular Lymphoma
The US FDA has approved Roche’s Lunsumio VELO for subcutaneous use in Relapsed or Refractory Follicular Lymphoma, cutting administration time to about one minute and supported by strong complete response data in later-line patients.
Lenalidomide | 22/12/2025 | By News Bureau | 289
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy